62876-43-1Relevant academic research and scientific papers
Synthetic Posttranslational Modifications: Chemical Catalyst-Driven Regioselective Histone Acylation of Native Chromatin
Amamoto, Yoshifumi,Aoi, Yuki,Nagashima, Nozomu,Suto, Hiroki,Yoshidome, Daisuke,Arimura, Yasuhiro,Osakabe, Akihisa,Kato, Daiki,Kurumizaka, Hitoshi,Kawashima, Shigehiro A.,Yamatsugu, Kenzo,Kanai, Motomu
, p. 7568 - 7576 (2017/06/14)
Posttranslational modifications (PTMs) of histones play an important role in the complex regulatory mechanisms governing gene transcription, and their dysregulation can cause diseases such as cancer. The lack of methods for site-selectively modifying nati
LYSOPHOSPHATIDYLSERINE DERIVATIVE
-
, (2016/10/07)
PROBLEM TO BE SOLVED: To provide a lysophosphatidylserine derivative or salt thereof. SOLUTION: The present invention provides a lysophosphatidylserine derivative or salt thereof, or a pharmaceutical composition or lysophosphatidylserine receptor function modulator including the compound or salt thereof. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT
LYSOPHOSPHATIDYLSERINE DERIVATIVE COMPRISING FATTY ACID SURROGATE
-
, (2016/10/08)
PROBLEM TO BE SOLVED: To provide a lysophosphatidylserine derivative to serve as a lysophosphatidylserine receptor function modulator or salt thereof, and a fatty acid surrogate which can be used as a synthetic intermediate of these compounds. SOLUTION: The present invention relates to, for example, a lysophosphatidylserine derivative of the following formula that is obtained by the condensation of the synthetic intermediate 3-(2-((3-(o-tolyloxy)benzil)oxy)phenyl)propanoic acid induced from o-cresol with a corresponding serine phosphoester compound having a hydroxy group. SELECTED DRAWING: None COPYRIGHT: (C)2016,JPOandINPIT
PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF
-
Page/Page column 86; 87, (2016/05/02)
Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).
HETEROCYCLIC MODULATORS OF HIF ACTIVITY FOR TREATMENT OF DISEASE
-
Paragraph 0355, (2014/03/25)
The present invention relates to compounds and methods which may be useful as inhibitors of HIF pathway activity for the treatment or prevention of cancer and other hypoxia-mediated diseases.
THERAPEUTIC SUBSTITUTED CYCLOPENTANES
-
Page/Page column 16, (2009/10/01)
Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
HDAC INHIBITORS
-
Page/Page column 25, (2008/06/13)
Compounds of formula (I) inhibit HDAC activity, wherein A, B and D independently represent =C- or =N-; W is a divalent radical -CH=CH- or CH2CH2-; R1 is a carboxylic acid group (-COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R2 is the side chain of a natural or non-natural alpha amino acid; z is 0 or 1; and Y, L1, and X1 are as defined in the claims.
Therapeutic Substituted Cyclopentanes
-
Page/Page column 9, (2008/06/13)
Therapeutic compounds are disclosed herein. ???????????
12-ARYL PROSTAGLANDIN ANALOGS
-
Page/Page column 52, (2010/11/08)
Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the ω-chain comprises a substituted phenyl, wherein at least one substituent
4,5,6-Trinor-3,7-inter-m-phenylene prostaglandin F1α analogs
-
, (2008/06/13)
This invention is a group of 4,5,6-trinor-3,7-inter-m-phenylene prostaglandin-type compounds and processes for making them. These compounds are useful for a variety of pharmacological purposes, including hypotensive control and inhibition of platelet aggr
